2 December 2020 - interim results/director share buying
Shares in the AIM-listed medical diagnostics company Omega Diagnostics have held firm during the recent strong rally, which is hardly surprising as investors move back into more cyclical stocks which should benefit from economic recovery. Stocks such as Omega which benefited from the pandemic have therefore been left behind in this run. The recently announced interim results for the six months to 30 September, which revealed a decline in revenues to £3.2m (2019: £4.5m) are largely irrelevant given the stage of the company's development. Of more interest is . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
